Special Meeting Annoucement
Special Meeting Announcement - January 17, 2015 - In Conversation with Dr. Eric Liu, Healing NET Foundation
As many of you know ASCO GI will be coming to San Francisco next week. NorCal CarciNet Community and the Neuroendocrine Carcinoid Cancer Awareness Network will be on hand as exhibitors at the conference. Before his flight back home to Nashville, Dr. Liu will be joining us on Saturday, January 17, 2015 from 9 am to noon at the Peninsula Jewish Community Center in Foster City for a breakfast conversation on NETs. Dr. Liu will bring us up to date on the latest in NETs from the ASCO GI conference as well as the latest news from the Healing NET Foundation. Please note we may have a few additional special out of town guests that will join the conversation as well.
This meeting will take place at the PJCC at 800 Foster City Blvd in Foster City.
There is no cost to attend this meeting and it is open to all - however we are requiring registration so that we can set up the room and provide breakfast to those in attendance. Please click here to register.
JNCI Monograph on Integrative Oncology
The Society for Integrative Oncology has published a first-of-its kind breast cancer clinical practice guidelines in the Journal of the National Cancer Institute Monographs coinciding with the 11th International Conference of the Society for Integrative Oncology in Houston, Texas at the end of October. NorCal CarciNet Community President, Josh Mailman contributed a perspective on Integrative Oncology to the Monograph entitled "A Patients' Perspective on Integrative Oncology: Getting Past the "War," Living With and Beyond Cancer.
Updates from the Ga68 Working Group
Ga-68 DOTATOC, Ga-68-labeled somatostatin analogs are important imaging agents to detect and manage neuroendocrine tumors (NETs). The SNMMI formed the 68Ga Users Group to advance the use of these imaging agents in the US. Members of the Users Group developed harmonized release criteria, an imaging manual, generic data collection forms and a draft informed consent form to aid the community in establishing investigator-sponsored trials. In October 2013, the Society of Nuclear Medicine and Molecular Imaging (SNMMI) received orphan drug designation for Ga-68 DOTATOC.
Click here to see the slides from the Gallium Information Session held in St. Louis during the SNMMI Annual Meeting on June 9th, 2014.
NorCal CarciNET Community continues to support the work of the 68Ga Users Group. Our president, Josh Mailman has been a member of the working group which meets monthly since January 2012.
Affordable Health Care Act Deadlines
March 31, 2014 marks the deadline for getting insurance under the Affordable Health Care Act (AHCA) for this year, with March 15, 2014 being the deadline if you would like the insurance to start on April 1, 2014. Open enrollment for 2015 will start on October 15, 2014 and end on December 15, 2014.
If you have questions about the AHCA, please see the presentation that was made to our group in December by the Cancer Legal Resource Foundation by clicking here.
NorCal CarciNet President Featured in Pathways
NorCal CarciNet Community President, Josh Mailman was featured in the Society of Nuclear Medicine and Molecular Imaging's Clinical Trials Pathways Newsletter in January, 2014. Josh's article "68Ga PET/CT Advances in the United States: A Personal Journey" chronicles the work that Josh did with the Gallium 68 working group to bring Ga68 imaging to the United States. To download a copy of Pathways click here.
Ga-68 DOTATOC - Orphan Drug Announcement
BREAKING NEWS – the radiopharmaceutical Gallium-68 (DOTA0-hel-Tyr3) octreotide (Ga-68 DOTATOC) has been designated as an orphan drug by the US Food and Drug Administration (FDA) for the management of neuroendocrine tumors. This designation is significant because it may lead to faster approval of the agent, which would greatly benefit carcinoid/NET patients in the United States. Click here to read the full release the Society of Nuclear Medicine and Molecular Imaging and from Josh Mailman, chairman of the Society’s Patient Advocacy Advisory Board and president of the NorCal CarciNET Community.
NorCal CarciNET / UCSF 2014 Patient Conference
2014 Neuroendocrine Tumor Patient Conference
Hosted by: NorCal CarciNET Community & UCSF Helen Diller Family Comprehensive Cancer Center
Sunday, January 19, 2014 - 9:00 am to 4:00 pm
NEW Location Krutch Theater (Clark-Kerr) on the UC Berkeley Campus
2601 Warring St., Bldg. 14, Clark Kerr Campus, Berkeley, CA 94720
Please join us for a day of discussion on the latest developments in neuroendocrine tumor (NET) research and treatment. Topics will range from discovery and diagnosis through treatment and living with cancer and feature experts from around the world. Open to both patients, caregivers and those interested in NETs.
NorCal CarciNET Community President Visits DC
During the month of October, Josh Mailman, President of NorCal CarciNet Community made two trips to Washington D.C. on behalf of the NET Community. During his first trip of the month Josh attended the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Patient Advocate Advisory meeting which he chairs.
Presentations from Society of Nuclear Medicine Patient Education Day.
On Sunday June 9th, 2013 the Society of Nuclear Medicine and Molecular Imaging Patient Advocacy Advisory Board (PAAB) held a patient education day at their annual meeting. The patient program is designed for patient and those who support them as well as the general public to learn more about molecular imaging and treatments. The day included a special NETs breakout in the afternoon covering specific imaging and treatments available for those with NETS delivered by international experts. NorCal CarciNet's Josh Mailman is the current chair of the PAAB and gave a keynote address at the conference.
We have linked the Agenda below to the online presentation. We hope you find the information useful.